Journal of Innovations in Pharmaceutical and Biological Sciences
Read the article
Visual summary · Journal of Innovations in Pharmaceutical and Biological Sciences

Multi-Target Pharmacological Evaluation of Embelin and Piperine against Rheumatoid Arthritis: A Network Pharmacology and Molecular Docking Study

Sulaiman Ahmad, Shaikh Mahmad kaif, Shaikh Mehmood Dawood

The question

What might Embelin and Piperine do against rheumatoid arthritis, and through which targets?

  • Rheumatoid arthritis is a lasting autoimmune inflammatory illness: the joint lining inflames, cartilage wears away, joints deteriorate and disability grows.
  • Conventional approaches are often tied to side effects and weak long-term success, which has prompted a search for safer plant treatments acting on several targets at once.

What was done

Twocompounds studied: Embelin and Piperine
GeneCardssource of the arthritis-linked targets
PPInetworks of protein-protein interaction
  • Network pharmacology and molecular docking were brought together to examine what the two compounds might do against arthritis.
  • Likely targets of the two compounds were found with SwissTargetPrediction and PubChem; the targets tied to rheumatoid arthritis came from the GeneCards database.
  • The targets common to both sides were then studied in protein-protein interaction networks, to pick out the critical hub genes.

Key findings

Finding 1 of 4
PI3K-Akt
signalling stood out among the pathways involved

Enrichment of GO and KEGG pathways showed that inflammatory and immune-regulatory pathways were considerably involved, the PI3K-Akt signalling pathway in particular.

Finding 2 of 4
Six
key hub genes discovered

Six key hub genes were discovered: HSP90AA1 and SRC, PIK3CA and JAK2, PTK2 and MET.

Finding 3 of 4
-7.2 kcal/mol
Piperine bound HSP90AA1; at JAK2 it reached -7.5 kcal/mol, similar to Tofacitinib

Piperine bound strongly to HSP90AA1 at -7.2 kcal/mol and to JAK2 at -7.5 kcal/mol, close to the standard treatment Tofacitinib at -7.5 kcal/mol.

Finding 4 of 4
Embelin
showed a positive affinity with HSP90AA1 and JAK2

Embelin showed a positive affinity with HSP90AA1 at -6.1 kcal/mol and with JAK2 at -5.8 kcal/mol.

Why it matters

  • The authors say the data indicate that the two compounds may have antiarthritic properties, by regulating inflammatory and immunological pathways at several targets.
  • The work used network pharmacology together with molecular docking, on targets drawn from databases.

How to cite

Sulaiman Ahmad, Shaikh Mahmad kaif, Shaikh Mehmood Dawood. Multi-Target Pharmacological Evaluation of Embelin and Piperine against Rheumatoid Arthritis: A Network Pharmacology and Molecular Docking Study. Journal of Innovations in Pharmaceutical and Biological Sciences. 2026;13(01):45-55. https://doi.org/10.56511/jipbs.2026.13106

Open the article